Ann: Teva Launches Generic Version of Axiron in United States, page-3

Results out show the generics have absolutely pounded Axiron since the start of this financial year. Can't imagine what the next quarterly is going to look like, before the court case is even heard. Over $10m in impairments as a result.

Impairment loss is a result of a re-assessment of the estimated future discounted cashflows from Axiron® assessing variables including the current market data for the Testosterone market in the United States and generic market penetration since 6 July 2017

Don't know how I ever got sucked into buying this rubbish a couple years back. Right up there with my worst investments.